21st Century Oncology Announces Launch of Initial Public Offering

        Print
| Source: 21st Century Oncology Holdings, Inc.

FORT MYERS, Fla., May 7, 2014 (GLOBE NEWSWIRE) -- 21st Century Oncology Holdings, Inc. ("21st Century Oncology" or "the Company") today announced that it has commenced an initial public offering of 13,333,333 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the "Commission"). The Company intends to grant the underwriters a 30-day option to purchase up to an additional 2,000,000 shares of common stock. The estimated price range for the initial public offering is $14.00 to $16.00 per share of common stock. The Company has applied to list its common stock on the New York Stock Exchange under the symbol "ICC."

The Company is also offering 1,500,000 shares of its Series A mandatory convertible junior non-voting preferred stock ("Series A preferred stock") in a concurrent public offering at the public offering price of $50.00 per share of Series A preferred stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 225,000 shares of Series A preferred stock. The Company has applied to list its Series A preferred stock on the New York Stock Exchange under the symbol "ICC PR."

The Company intends to use the net proceeds from the offerings to repay outstanding debt, to pay related fees and expenses and for general corporate purposes.

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Wells Fargo Securities, LLC are serving as joint book-running managers for the offerings. KeyBanc Capital Markets Inc., SunTrust Robinson Humphrey, Inc., Avondale Partners, LLC and Piper Jaffray & Co. are serving as co-managers for the offerings.

Each of the offerings will be made only by means of a prospectus. A copy of the preliminary prospectus related to each offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at (866) 803-9204 or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York, 10152, by telephone at (800) 326-5897 or email a request to cmclientsupport@wellsfargo.com.

The registration statement on Form S-1 relating to these securities has been filed with the Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About 21st Century Oncology Holdings, Inc.

21st Century Oncology Holdings, Inc. is the largest global, physician led provider of Integrated Cancer Care Services. The Company offers a comprehensive range of cancer treatment services, focused on delivering academic quality, cost-effective patient care in personal and convenient settings. The Company operates 185 treatment centers, including 150 centers located in 16 U.S. states. The Company also operates 35 centers located in six countries in Latin America. The Company holds market leading positions in most of its domestic local markets and abroad.

Bryan J. Carey
President and CFO
239-931-7285


Investors:
Nick Laudico
The Ruth Group
646-536-7030